<?xml version="1.0"?>
<Articles JournalTitle="Acta Biochimica Iranica">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Acta Biochimica Iranica</JournalTitle>
      <Issn>0001-5261</Issn>
      <Volume>2026</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="epublish">
        <Year>2026</Year>
        <Month>06</Month>
        <Day>20</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Alterations and Correlation of Metabolic Hormones (Irisin, Amylin, SIRT1), Inflammatory Marker, and Vitamins D3 and B3 in Type 2 Diabetes patients with or without Diabetic Nephropathy</title>
    <FirstPage>71</FirstPage>
    <LastPage>79</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Sinhareeb</FirstName>
        <LastName>Wajdi</LastName>
        <affiliation locale="en_US">Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Matin</FirstName>
        <LastName>Mohyadini</LastName>
        <affiliation locale="en_US">Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Mohamadhudifa</FirstName>
        <LastName>Hasanain</LastName>
        <affiliation locale="en_US">Ministry of Health, Salah Aldeen Health Department, Balad General Hospital, Iraq.</affiliation>
      </Author>
      <Author>
        <FirstName>Walaa E</FirstName>
        <LastName>Jassim</LastName>
        <affiliation locale="en_US">Department of Medical Laboratory Techniques, Faculty of Health and Medical Technologies, Central Medical University, Baghdad, Iraq.</affiliation>
      </Author>
      <Author>
        <FirstName>S. Zahra</FirstName>
        <LastName>Bathaie</LastName>
        <affiliation locale="en_US">Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2026</Year>
        <Month>04</Month>
        <Day>13</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2026</Year>
        <Month>04</Month>
        <Day>27</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Objectives: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease in patients with type 2 diabetes mellitus (T2DM), involving complex metabolic, inflammatory, and hormonal dysregulation. This study investigated the circulating levels and interrelationships between Irisin, Amylin, SIRT1, vitamin D3 (Vit-D3), vitamin B3 (Vit-B3), and serum amyloid A (SAA) among healthy controls, patients withT2DM, and DN patients.
&#xD;

Methods: In this case-control study, 150 male participants (50 per group; aged 40&#x2013;65 years) were enrolled and matched for age and BMI. Fasting samples were used to measure routine biochemical parameters, HOMA-IR, HbA1c, and specific markers (Irisin, Amylin, SIRT1, SAA, Vit-B3 via ELISA; Vit-D3 via CLIA).
&#xD;

Results: Both diabetic groups had elevated FBS, HbA1c, insulin, HOMA-IR, and BMI versus controls. DN group exhibited marked renal impairment (higher urea, creatinine, microalbumin; lower eGFR). Vit-D3 and Vit-B3 were significantly lower in patients with T2DM and DN, with a further reduction in Vit-B3 in DN. Serum amyloid A levels were unexpectedly lower in diabetic groups. The order of amylin levels was: control &gt; T2DM &gt; DN, while Irisin and SIRT1 were in the opposite order. The association between Irisin and SIRT1 was weak in DN group. Amylin-SIRT1 was negative in T2DM and positive in DN groups. Vit-B3 correlated positively with SIRT1 only in DN group. Serum amyloid A was negatively correlated with SIRT1 in diabetic groups. This parameter correlated with HbA1c in DN group.
&#xD;

Conclusions: These findings highlight potential compensatory roles of Irisin-SIRT1, niacin-NAD+ dependency, and atypical serum amyloid A regulation, suggesting novel biomarkers and therapeutic avenues (e.g., NAD+ precursors, SIRT1 modulation) for diabetic kidney disease.</abstract>
    <web_url>https://abi.tums.ac.ir/index.php/abi/article/view/185</web_url>
    <pdf_url>https://abi.tums.ac.ir/index.php/abi/article/download/185/138</pdf_url>
  </Article>
</Articles>
